.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Precision Medicine: A New Frontier for Advanced Cholangiocarcinoma

EP. 1: Diagnosing CCA

October 21st 2019

EP. 2: Heterogeneity of CCA

October 21st 2019

EP. 3: Tumor Markers in CCA

October 21st 2019

EP. 4: Prevalence of CCA

October 21st 2019

EP. 5: Adjuvant Chemotherapy for CCA

October 21st 2019

EP. 6: Radiation Therapy for CCA

October 21st 2019

EP. 7: Frontline Therapy for CCA

October 21st 2019

EP. 8: Second-Line Therapy for CCA

October 21st 2019

EP. 9: Molecular Testing for CCA

October 21st 2019

EP. 10: Mutual Exclusivity in CCA

October 21st 2019

EP. 11: Infigratinib for CCA

October 21st 2019

EP. 12: FGFR Inhibitors in Development for CCA

October 21st 2019

EP. 13: Ivosidenib for Advanced IDH1-Mutated CCA

October 21st 2019

EP. 14: ClarIDHy Phase III Trial of Ivosidenib in CCA

October 21st 2019

EP. 15: Final Thoughts on CCA

October 21st 2019